Search research articles
Contact Us
Filters
Showing results (11-20 of 15) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 15 results.
Journal of Translational Medicine
|
March 4, 2023
Metagenomic analysis examines oral microbiome changes and interplay with immune response following prenatal total oral rehabilitation
Tong Tong Wu, Michael Sohn, Samantha Manning, et al.
Biorxiv : the Preprint Server for Biology
|
January 13, 2025
Immune Checkpoint Molecules as Biomarkers of <i>Staphylococcus aureus</i> Bone Infection and Clinical Outcome
Motoo Saito, Katya A McDonald, Alex K Grier, et al.
Cancer
|
December 22, 2017
Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma
David A Reardon, Andrew B Lassman, David Schiff, et al.
Cancer Medicine
|
August 25, 2019
Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma
Eudocia Q Lee, Alona Muzikansky, Dan G Duda, et al.
Frontiers in Immunology
|
September 11, 2023
Multi-omics analysis identifies IgG2b class-switching with ALCAM-CD6 co-stimulation in joint-draining lymph nodes during advanced inflammatory-erosive arthritis
H Mark Kenney, Javier Rangel-Moreno, Yue Peng, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 15) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 15 results.
Journal of Translational Medicine
|
March 4, 2023
Metagenomic analysis examines oral microbiome changes and interplay with immune response following prenatal total oral rehabilitation
Tong Tong Wu, Michael Sohn, Samantha Manning, et al.
Biorxiv : the Preprint Server for Biology
|
January 13, 2025
Immune Checkpoint Molecules as Biomarkers of <i>Staphylococcus aureus</i> Bone Infection and Clinical Outcome
Motoo Saito, Katya A McDonald, Alex K Grier, et al.
Cancer
|
December 22, 2017
Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma
David A Reardon, Andrew B Lassman, David Schiff, et al.
Cancer Medicine
|
August 25, 2019
Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma
Eudocia Q Lee, Alona Muzikansky, Dan G Duda, et al.
Frontiers in Immunology
|
September 11, 2023
Multi-omics analysis identifies IgG2b class-switching with ALCAM-CD6 co-stimulation in joint-draining lymph nodes during advanced inflammatory-erosive arthritis
H Mark Kenney, Javier Rangel-Moreno, Yue Peng, et al.
Page
of 2